BMEA vs. TRDA, HROW, LXRX, HRTX, PEPG, NGNE, MRSN, CDMO, FULC, and ANNX
Should you be buying Biomea Fusion stock or one of its competitors? The main competitors of Biomea Fusion include Entrada Therapeutics (TRDA), Harrow Health (HROW), Lexicon Pharmaceuticals (LXRX), Heron Therapeutics (HRTX), PepGen (PEPG), Neurogene (NGNE), Mersana Therapeutics (MRSN), Avid Bioservices (CDMO), Fulcrum Therapeutics (FULC), and Annexon (ANNX). These companies are all part of the "pharmaceutical preparations" industry.
Biomea Fusion (NASDAQ:BMEA) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.
Biomea Fusion received 20 more outperform votes than Entrada Therapeutics when rated by MarketBeat users. However, 73.33% of users gave Entrada Therapeutics an outperform vote while only 59.62% of users gave Biomea Fusion an outperform vote.
Biomea Fusion currently has a consensus price target of $53.13, indicating a potential upside of 361.96%. Entrada Therapeutics has a consensus price target of $21.00, indicating a potential upside of 71.85%. Given Biomea Fusion's higher possible upside, equities analysts plainly believe Biomea Fusion is more favorable than Entrada Therapeutics.
Biomea Fusion has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -5.18%. Entrada Therapeutics' return on equity of -2.89% beat Biomea Fusion's return on equity.
Biomea Fusion has a beta of -0.53, indicating that its share price is 153% less volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of -0.5, indicating that its share price is 150% less volatile than the S&P 500.
In the previous week, Entrada Therapeutics had 1 more articles in the media than Biomea Fusion. MarketBeat recorded 5 mentions for Entrada Therapeutics and 4 mentions for Biomea Fusion. Biomea Fusion's average media sentiment score of 1.01 beat Entrada Therapeutics' score of 0.76 indicating that Biomea Fusion is being referred to more favorably in the media.
96.7% of Biomea Fusion shares are held by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are held by institutional investors. 26.3% of Biomea Fusion shares are held by company insiders. Comparatively, 7.6% of Entrada Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Entrada Therapeutics has higher revenue and earnings than Biomea Fusion. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.
Summary
Entrada Therapeutics beats Biomea Fusion on 9 of the 17 factors compared between the two stocks.
Get Biomea Fusion News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMEA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BMEA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biomea Fusion Competitors List
Related Companies and Tools
